Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Omeros (OMER) Q3 2026: YARTEMLEA Revenue Rises 30% as Adjusted Earnings Top Estimates

Omeros (OMER) Q3 2026: YARTEMLEA Revenue Rises 30% as Adjusted Earnings Top Estimates

Key Takeaways

  • Omeros reported third quarter 2026 adjusted earnings of $0.06 per share, beating the analyst consensus of $0.01 per share.
  • YARTEMLEA gross revenue climbed to $41.8 million, up roughly 30% from $32.2 million in the prior quarter, while net revenue rose to $35.9 million.
  • The company posted a GAAP net loss of $57.4 million, or $0.79 per share, driven mainly by a $62.0 million non-cash mark-to-market loss tied to its 2029 convertible notes.
  • Operating income improved to $4.5 million, and the company generated its second consecutive quarter of positive operating cash flow at $13.3 million.
  • Cash and short-term investments stood at $95.3 million as of September 30, 2026.
  • Shares fell about 10% in after-hours trading as investors weighed the widened GAAP loss alongside a negative European regulatory opinion on narsoplimab.
  • For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for additional context.
  • To discover similar opportunities across the market, explore Trending AI Robots for AI-driven trading insights.

Why This Quarter Matters

Omeros Corporation's third quarter 2026 results mark an important checkpoint for a biotechnology firm that has moved from pre-revenue development into commercial operations. With YARTEMLEA now serving as the main revenue source following its FDA approval for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), each report tests how well the product is executing commercially and gaining reimbursement traction. I am watching closely to see whether the drug can keep delivering sequential growth, broaden outpatient use, and help steer the company toward steadier profitability. Balance sheet items linked to the 2029 convertible notes also add layers of non-cash volatility that can obscure the underlying operational picture.

Quarterly Results in Detail

For the period ended September 30, 2026, Omeros posted adjusted net income of $4.7 million, or $0.06 per share, which cleared the consensus estimate of $0.01 per share. YARTEMLEA gross revenue reached $41.8 million, reflecting a 29.6% sequential increase from $32.2 million and surpassing the approximate $37.3 million analyst target. Net revenue advanced 26% to $35.9 million from $28.5 million in the previous quarter. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the biotech space.

On a GAAP basis, the company recorded a net loss of $57.4 million, or $0.79 per share, largely due to a $62.0 million non-cash mark-to-market loss on a derivative tied to the 2029 convertible notes. Setting those items aside, performance improved year-over-year. Operating income climbed to $4.5 million from $0.1 million, and operating cash flow stayed positive at $13.3 million. The gross-to-net adjustment widened to 14.0% from 11.5%, reflecting higher 340B program purchases that management views as a sign of expanding customer reach.

How the Market Responded

Even with the beats on adjusted earnings and revenue, shares of OMER declined roughly 10% in after-hours trading. The move appears driven by several factors. The larger GAAP loss, stemming from the non-cash derivative adjustment, drew attention from some investors. In addition, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion in October 2026 on the marketing authorization application for narsoplimab in TA-TMA after re-examination. While the U.S. launch continues as planned, the European development tempers expectations for broader international revenue potential.

What to Watch Going Forward

The key question ahead centers on whether YARTEMLEA can sustain its growth trajectory in the United States. Management has highlighted expanding adoption at transplant centers, broader formulary inclusion, and greater outpatient utilization as important drivers. Keeping an eye on the gross-to-net adjustment will be useful, as increased 340B participation can weigh on net revenue while pointing to a larger customer base.

Regulatory news will also stay in focus. The negative CHMP opinion on narsoplimab narrows near-term options outside the U.S., so any updates on appeals or next steps merit attention. On the financial side, maintaining positive operating cash flow and handling obligations related to the 2029 notes will influence how the market assesses balance-sheet considerations.

Pipeline updates provide additional context over time. Omeros is advancing next-generation MASP-2 programs, the OMS527 candidate for cocaine use disorder, and its oncology efforts. While these represent longer-term opportunities, meaningful data or milestones could shift attention toward the company’s wider therapeutic reach beyond YARTEMLEA. Investors should balance commercial progress, regulatory outcomes, and pipeline developments rather than viewing any single quarter in isolation.

Using AI Tools in My Research

When evaluating names like OMER alongside other biotechs, I find Tickeron’s AI Screener helpful for quickly filtering technical patterns, fundamentals, and performance metrics. It lets me scan for comparable opportunities without spending hours on manual review, which keeps my process more efficient as market conditions evolve.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OMER

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


OMER's RSI Oscillator ascends from oversold territory

The RSI Oscillator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 28 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.586). P/E Ratio (8.812) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Industry
Biotechnology
Address
201 Elliott Avenue West
Phone
+1 206 676-5000
Employees
175
Web
https://www.omeros.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.